Medicine & Life Sciences
Cholangiocarcinoma
100%
Neoplasms
61%
Biliary Tract Neoplasms
42%
gemcitabine
28%
Pancreatic Neoplasms
28%
Survival
24%
Adenocarcinoma
23%
Receptor, Fibroblast Growth Factor, Type 2
23%
Therapeutics
22%
Hepatocellular Carcinoma
22%
Mutation
21%
Fibroblast Growth Factor Receptors
18%
Atlases
17%
Safety
17%
Genome
16%
Progression-Free Survival
15%
Oncolytic Viruses
14%
Maximum Tolerated Dose
14%
Cisplatin
13%
Sorafenib
13%
Immunotherapy
13%
Oncolytic Virotherapy
11%
Gallbladder Neoplasms
10%
130-nm albumin-bound paclitaxel
10%
Pharmacokinetics
10%
Clinical Trials
10%
Circulating Tumor DNA
10%
Precision Medicine
10%
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
10%
Isocitrate Dehydrogenase
10%
Genes
10%
ivosidenib
9%
Neoplasm Genes
9%
Drug Therapy
9%
TH 302
9%
HhAntag691
9%
Carcinoma
7%
Vesicular Stomatitis
7%
High-Throughput Nucleotide Sequencing
7%
Bevacizumab
7%
Liver
7%
Network Meta-Analysis
6%
Tumor Burden
6%
Biliary Tract
6%
Neoplasm Metastasis
6%
Liver Transplantation
6%
Viruses
5%
Oncogenes
5%
trifluridine tipiracil
5%
Confidence Intervals
5%